奈达铂与洛铂同步放化疗治疗局部晚期宫颈癌的疗效观察

Efficacy of concurrent chemoradiotherapy with nedaplatin and lobaplatin for locally advanced cervical cancer

目的探讨奈达铂与洛铂同步放化疗治疗局部晚期宫颈癌的临床疗效及不良反应。方法选取2015年1月至2016年1月间陕西省扶风县人民医院收治的80例局部晚期宫颈癌患者,根据患者入院时间顺序交替分为观察组与对照组,每组40例。观察组患者采用奈达铂3周方案同步放化疗,对照组患者采用洛铂3周方案同步放化疗,比较两组患者的疗效及不良反应。结果观察组患者临床总有效率为85.0%,明显高于对照组患者的62.5%,两组比较,差异有统计学意义(P<0.05)。观察组患者治疗后,肿瘤最大直径为(1.71±0.87)cm,明显小于治疗前的(4.75±1.59)cm,对照组患者治疗后肿瘤最大直径为(2.31±1.09)cm,明显小于治疗前的(4.72±1.54)cm,差异均有统计学意义(均P<0.05)。且观察组患者治疗后肿瘤最大直径小于对照组患者,组间比较,差异有统计学意义(P<0.05)。观察组患者不良反应总发生率为47.5%,低于对照组患者的82.5%,组间比较,差异有统计学意义(P<0.05)。结论奈达铂同步放化疗治疗局部晚期宫颈癌患者的临床疗效好,不良反应较轻,患者耐受性高,值得临床推广。

Objective To investigate the efficacy and adverse reactions of concurrent chemoradio- therapy with nedaplatin and lobaplatin for locally advanced cervical cancer. Methods Eighty patients with locally advanced cervical cancer admitted to Fufeng County People＇s Hospital from January 2015 to June 2015 were selected as the subjects. According to the time of admission, patients were divided into an obser- vation group and a control group with 40 patients in each group. Patients in the observation group received concurrent chemoradiotherapy with nedaplatin for 3 weeks and patients in the control group received concur- rent chemoradiotherapy with lobaplatin for 3 weeks. The efficacy and adverse reactions of were compared be- tween the two groups. Results The overall efficacy rate was 85.0% in the observation group which was significantly higher than 62. 5% in the control group （P 〈0. 05）. For patients in the observation group, the maximum tumor diameter （MTD） was （ 1.71 ± 0. 87 ） cm after treatment, which was significantly smaller than （4.75± 1.59） cm of before treatment. For patients in the control group, MTD was （2. 31 ± 1.09） cm after treatment, which was significantly smaller than （4.72 ± 1.54） cm of before treatment （ all P 〈 0. 05 ）. Incidence of adverse reactions was significantly lower in the observation group （47. 5% ） than in the control group （82. 5 % ） （P 〈 O. 05 ）. Conclusion Concurrent chemoradiotherapy with nedaplatin in the treatmentof locally advanced cervical cancer shows good clinical efficacy, few adverse reactions and high tolerance, which is worthy of clinical promotion.